SCHEMBL359033

SCHEMBL359033

COc1ccc(NC(=O)c2csc3cnc(N[C@H]4CCCC[C@H]4N)nc23)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SYK P43405 19/20 0.61
IRAK4 Q9NWZ3 4/20 0.56
IRAK1 P51617 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360035 1.00 SYK (0.61) SYKIRAK4IRAK1
SCHEMBL359660 0.86 SYK (0.65) SYKIRAK4IRAK1
SCHEMBL358463 0.85 SYK (0.65) SYKIRAK4IRAK1
SCHEMBL358573 0.85 SYK (0.65) SYKIRAK4IRAK1
SCHEMBL19265945 0.84 SYK (0.69) SYKIRAK4IRAK1
SCHEMBL359710 0.84 SYK (0.69) SYKIRAK4IRAK1
SCHEMBL358375 0.84 SYK (0.69) SYKIRAK4IRAK1
SCHEMBL358871 0.83 IRAK4 (0.79) SYKIRAK4IRAK1
SCHEMBL19677223 0.83 IRAK4 (0.56) SYKIRAK4IRAK1
SCHEMBL19677204 0.83 MAPT (0.47) SYKIRAK4IRAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023589-B2 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators HOFFMANN-LA ROCHE INC. (US) 2018-07-17 US disclosed
US-20160207936-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS HOFFMANN-LA ROCHE INC. 2016-07-21 US disclosed
US-20140303149-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS HOFFMANN-LA ROCHE INC. (US) 2014-10-09 US disclosed
US-20120015962-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS ARORA NIDHI (US) 2012-01-19 US disclosed
US-20120015962-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS ARORA NIDHI (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160207936-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK4, IRAK1, IRAK2 SYK 634/4885IRAK4 1/4885IRAK1 2/4885
US-20140303149-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK4, IRAK1, IRAK2 SYK 634/4885IRAK4 1/4885IRAK1 2/4885
US-10023589-B2 Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators IRAK4, IRAK1, IRAK2 SYK 634/4885IRAK4 1/4885IRAK1 2/4885
US-20120015962-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK4, IRAK1, IRAK2 SYK 634/4885IRAK4 1/4885IRAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.